Keramida G, Peters AM: Fallacy of quantifying lymphoma activity by scaling to the liver in [18F]fluorodeoxyglucose positron emission tomography (Deauville criteria). J Clin Oncol 33:4120-4121, 2015
Barrington SF, Mikhaeel NG, Kostakoglu L, et al: Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32:3048-3058, 2014
Keramida G, Dizdarevic S, Bush J, et al: Quantification of tumour F-FDG uptake: Normalise to blood glucose or scale to liver uptake? Eur Radiol 25:2701-2708, 2015
Ishizu K, Nishizawa S, Yonekura Y, et al: Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med 35:1104-1109, 1994
Lindholm P, Minn H, Leskinen-Kallio S, et al: Influence of the blood glucose concentration on FDG uptake in cancer: A PET study. J Nucl Med 34:1-6, 1993
Hallett WA, Marsden PK, Cronin BF, et al: Effect of corrections for blood glucose and body size on [18F]FDG PET standardised uptake values in lung cancer. Eur J Nucl Med 28:919-922, 2001
Boellaard R, Delgado-Bolton R, Oyen WJ, et al: FDG PET/CT: EANM procedure guidelines for tumour imaging: Version 2.0. Eur J Nucl Med Mol Imaging 42:328-354, 2015
Barrington SF, Mikhaeel NG, Kostakoglu L, et al: Reply to B. Bennani-Baiti et al, H.J.A. Adams et al, E. Laffon et al, and E.A. Hawkes, et al: J Clin Oncol 33:1221-1223, 2015
